In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
The Perverse Incentive: A Unified Approach to Patient Engagement
In operationalising a clinical trial, there are an increasing number of patient facing technologies to aid data collection, enable patient support and improve retention and compliance, with the potential to benefit patients and sponsors alike. Learn more in this recent International Clinical Trials (ICT) article on the need for a unified approach to patient engagement.
-
ICON Acquires MeDiNova Research Site in Europe & Africa
This recent Applied Clinical Trials article discusses ICON's acquisition of majority shareholding in MeDiNova Research, a site network with research sites in Europe and Africa, granting our company the right to acquire the remaining shares in the company by the third quarter of 2020. MeDiNova Research currently has a network of 33 active clinical research sites in the UK, Spain, South Africa, Poland and Romania.
-
The Digital Trial: How Technology Is Changing Trial Design, Start-Up And Close-Out
The constant data stream from patients’ mobile devices and sensors generate large datasets that are difficult to analyze manually—just one motion sensor gathering data from a few dozen patients creates nearly one billion data points per day (ICON). To understand these large datasets, AI and machine learning are necessary to automate analyses. Incorporating this technology can lead to faster and more transparent access to data. In addition, it can help sponsors collect the right data to support submission and filing for regulatory review, and, in the end, speed a product’s path to approval and reduce time to market. In this Clinical Informatics News article, featuring commentary from ICON expert Marie McCarthy, leveraging technology to accelerate study close-out is further discussed.
-
Patient Engagement Web Platform from ICON Bolsters Clinical Connectivity
An Outsourcing Pharma article featuring commentary from experts EB McLindon & Gretchen Goller, on ICON’s new web-based patient engagement platform to provide patients with study-specific information and connectivity.
-
US Healthcare Reform Scenarios
There is growing interest among politicians and the public for significant change of the US healthcare system, popularising the phrase "Medicare for All". Our Pricing and Market Access team looked at three scenarios based on actual proposals.
-
ICON Introduces New Platform for Potential Trial Participants
A Clinical Trials Arena article featuring commentary from expert EB McLindon, following our announcement of ICON's new patient engagement platform to support people interested in participating in clinical trials by offering study specific information.
-
A New Horizon
A PharmaTimes article featuring commentary from Tom O’Leary on the future of AI in healthcare. O’Leary discusses how the key to maximising AI’s involvement in pharma development is to utilise its ability to draw distinctions and correlations, which would otherwise elude human observation. However, also notes the potential for AI is most exciting when paired with human experience, creativity and instinct.
-
Adopting mHealth Technologies in CV Trials
A Pharmafile article authored by Marie McCarthy and Jack Martin on the use of mHealth technologies in cardiovascular trials. The article discusses how, with the right approach and expert guidance, mHealth can help to collect new types of data, make trials more patient centric (improving recruitment, retention and compliance) and improve operational efficiency.
-
Rare disease trials Q&A
A Pharmaceutical Market Europe (PME) Q&A article authored by Gretchen Goller and Valerie Legrand, discussing the challenges of rare disease trials, including those of recruitment and retention unique to rare disease studies. The article also provides insights on solutions to these challenges.
-
ICER's Growing Impact On Drug Pricing And Reimbursement
Read Forbes' original article referencing the ICON whitepaper ‘The Role of ICER as an Independent HTA Organisation’, exploring how ICER may have a greater impact on payer decision-making than expected and can be viewed as a ‘decision resource’ for budgetary and formulary policy decision making.
